SAVA
Cassava Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.32
+2.33%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | 936.0K | — | 89.4M | 68.0M |
| Gross Profit | — | (936.0K) | — | (89.4M) | (68.0M) |
| Operating Expenses | |||||
| R&D Expense | 26.6M | 26.6M | 69.6M | 89.4M | 68.9M |
| SG&A Expense | 68.8M | 68.8M | 71.8M | 16.5M | 12.0M |
| General & Admin Expense | 68.8M | 68.8M | 71.8M | 16.5M | 12.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (936.0K) | — | (89.4M) | (68.9M) |
| Total Operating Expenses | 95.4M | 94.5M | 141.4M | 16.5M | 12.0M |
| Cost and Expenses | 95.4M | 95.4M | 141.4M | 106.0M | 80.0M |
| Operating Income (EBIT) | (95.4M) | (95.4M) | (141.4M) | (106.0M) | (80.0M) |
| Non-Operating | |||||
| Interest Income | 4.6M | 4.6M | 8.5M | 7.8M | 2.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 4.6M | 4.6M | 8.5M | 7.8M | 2.8M |
| Other Non-Op Income/Expense | 4.4M | 4.4M | 117.1M | 8.7M | 3.8M |
| Non-Operating Income (excl Interest) | (35.4M) | — | 832.0K | — | — |
| EBT (Pre-Tax Income) | (91.0M) | (91.0M) | (24.3M) | (97.2M) | (76.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (91.0M) | (91.0M) | (24.3M) | (97.2M) | (76.2M) |
| Earnings from Cont. Ops | (91.0M) | (91.0M) | (24.3M) | (97.2M) | (76.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (91.0M) | (91.0M) | (68.1M) | (97.2M) | (76.2M) |
| Per Share | |||||
| Basic EPS | ($1.88) | ($1.88) | ($0.53) | ($2.32) | ($1.80) |
| Diluted EPS | ($1.88) | ($1.88) | ($0.52) | ($2.32) | ($1.80) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 48.3M | 48.3M | 46.3M | 41.9M | 40.2M |
| Diluted Shares Outstanding | 48.3M | 48.3M | 46.6M | 41.9M | 40.2M |
| Profitability Metrics | |||||
| EBITDA | (94.5M) | (94.5M) | (141.1M) | (104.4M) | (78.7M) |
| D&A | 936.0K | 936.0K | 1.1M | 1.5M | 1.3M |
| EBIT | (60.0M) | (95.4M) | (142.3M) | (106.0M) | (80.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025